Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H19NO2.ClH |
Molecular Weight | 209.714 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC[C@@H](C)C[C@H](N)CC(O)=O
InChI
InChIKey=CFMZXQJDAJXNHS-WLYNEOFISA-N
InChI=1S/C9H19NO2.ClH/c1-3-4-7(2)5-8(10)6-9(11)12;/h7-8H,3-6,10H2,1-2H3,(H,11,12);1H/t7-,8+;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C9H19NO2 |
Molecular Weight | 173.2527 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00738738
Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:09:08 GMT 2023
by
admin
on
Fri Dec 15 16:09:08 GMT 2023
|
Record UNII |
MJ3F8ZA7Q1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
UU-112
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
610300-00-0
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
DBSALT002136
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
300000044507
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
11701275
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
MJ3F8ZA7Q1
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103836
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
DTXSID40976533
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY | |||
|
C83786
Created by
admin on Fri Dec 15 16:09:08 GMT 2023 , Edited by admin on Fri Dec 15 16:09:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |